Ono Pharmaceutical and Phylo have announced a new collaboration focused on bringing agentic AI into biomedical research. The companies said the partnership will introduce Biomni Lab, Phylo’s AI platform, to support discovery scientists as part of Ono’s research efforts.
According to the announcement, the centerpiece of the deal is Biomni Lab, which Phylo describes as an agentic AI platform for biomedical research. The stated goal is to embed AI capabilities alongside scientists involved in discovery work, signaling a push to make these tools part of day-to-day research activity rather than a separate experimental layer.
The partnership links a major pharmaceutical company with a specialist in AI for life sciences at a time when drug developers are increasingly exploring how advanced software can assist research teams. In this case, the emphasis is on giving discovery scientists direct access to agentic AI designed for biomedical tasks.
While the announcement highlights the strategic intent of the collaboration, the trimmed release does not outline broader operational details beyond the partnership and the use of Biomni Lab. Even so, the move shows how pharmaceutical research groups and AI companies are continuing to align around tools aimed at supporting early-stage scientific discovery.
